Advertisement
U.S. markets close in 2 hours 4 minutes
  • S&P 500

    5,252.18
    +3.69 (+0.07%)
     
  • Dow 30

    39,778.80
    +18.72 (+0.05%)
     
  • Nasdaq

    16,379.41
    -20.12 (-0.12%)
     
  • Russell 2000

    2,124.96
    +10.61 (+0.50%)
     
  • Crude Oil

    83.01
    +1.66 (+2.04%)
     
  • Gold

    2,242.00
    +29.30 (+1.32%)
     
  • Silver

    24.97
    +0.21 (+0.86%)
     
  • EUR/USD

    1.0799
    -0.0030 (-0.28%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2626
    -0.0012 (-0.09%)
     
  • USD/JPY

    151.3740
    +0.1280 (+0.08%)
     
  • Bitcoin USD

    70,823.62
    +1,911.24 (+2.77%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Amgen quarterly revenue dips 3% but profit tops Street expectations

By Deena Beasley

July 30 (Reuters) - Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

The U.S. biotechnology company said adjusted earnings per share rose 4% to $3.97, while Wall Street analysts, on average, expected $3.56 per share, according to IBES data from Refinitiv. A lower number of outstanding shares drove the earnings beat.

Amgen reported a net profit of $2.17 billion, or $3.57 per share, for the quarter, compared with a profit of $2.29 billion, or $3.50 per share, a year ago.

Total revenue of $5.87 billion, while lower than a year ago, topped analysts' estimates of $5.66 billion.

Sales of potent cholesterol fighter Repatha rose 3% to $152 million, below Wall Street estimates of $157 million. Sales of Amgen's new migraine drug Aimovig totaled $83 million for the quarter, beating the $77.4 million projected by analysts.

But sales of Neulasta, which fights infections by boosting white blood cells, fell 25% to $824 million, while sales of kidney drug Sensipar dropped 71% to $122 million as competition from cheaper generics and biosimilars increased.

The company still raised the lower end of its full-year outlook and now expects adjusted earnings of $13.75 to $14.30 per share on revenue of $22.4 billion to $22.9 billion. It had previously forecast $13.25 to $14.30 per share on revenue of $22 billion to $22.9 billion.

(Reporting By Deena Beasley Editing by Bill Berkrot)

Advertisement